Search research articles
Contact Us
Filters
Showing results (271-280 of 353) with videos related to
Page
of 36
Sort By:
BJU International
|
June 28, 2025
Impact of the R.E.N.A.L. complexity score on outcomes of stereotactic ablative body radiotherapy for primary renal cell carcinoma
Muhammad Ali, Mathias Bressel, David Chang, et al.
Journal of Geriatric Oncology
|
September 8, 2023
Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: Analysis of an Australian real-world cohort
Michael Fernando, Angelyn Anton, Andrew Weickhardt, et al.
BJU International
|
March 8, 2021
UpFrontPSMA: a randomized phase 2 study of sequential <sup>177</sup> Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol)
Nattakorn Dhiantravan, Louise Emmett, Anthony M Joshua, et al.
Frontiers in Medicine
|
December 5, 2022
AlphaBet: Combination of Radium-223 and [<sup>17</sup> <sup>7</sup>Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)
Louise Kostos, James P Buteau, Theresa Yeung, et al.
European Urology
|
October 30, 2025
Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [<sup>177</sup>Lu]Lu-PSMA-617
Heidi Fettke, Louise Kostos, Maria Docanto, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 22, 2026
Thrombotic Microangiopathy in Patients Treated with <sup>177</sup>Lu-PSMA Combination Therapies
Joanna C Chan, Mitchell T Carroll, Nadia Hitchen, et al.
European Urology Oncology
|
December 10, 2023
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis
Francisco Gomez-Veiga, Russell Z Szmulewitz, Jeffrey Holzbeierlein, et al.
Cancer Immunology Research
|
October 21, 2018
Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs
Brian J Christmas, Christine I Rafie, Alexander C Hopkins, et al.
Future Oncology (London, England)
|
June 30, 2025
Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review
Paul E Dato, Jose De La Cerda, Andrew J Armstrong, et al.
Future Oncology (London, England)
|
May 11, 2026
Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols
Neal D Shore, Karim Fizazi, Michael Thomas Schweizer, et al.
Page
of 36
Search research articles
Search
Showing results (271-280 of 353) with videos related to
Sort By:
Page
of 36
BJU International
|
June 28, 2025
Impact of the R.E.N.A.L. complexity score on outcomes of stereotactic ablative body radiotherapy for primary renal cell carcinoma
Muhammad Ali, Mathias Bressel, David Chang, et al.
Journal of Geriatric Oncology
|
September 8, 2023
Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: Analysis of an Australian real-world cohort
Michael Fernando, Angelyn Anton, Andrew Weickhardt, et al.
BJU International
|
March 8, 2021
UpFrontPSMA: a randomized phase 2 study of sequential <sup>177</sup> Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol)
Nattakorn Dhiantravan, Louise Emmett, Anthony M Joshua, et al.
Frontiers in Medicine
|
December 5, 2022
AlphaBet: Combination of Radium-223 and [<sup>17</sup> <sup>7</sup>Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)
Louise Kostos, James P Buteau, Theresa Yeung, et al.
European Urology
|
October 30, 2025
Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [<sup>177</sup>Lu]Lu-PSMA-617
Heidi Fettke, Louise Kostos, Maria Docanto, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 22, 2026
Thrombotic Microangiopathy in Patients Treated with <sup>177</sup>Lu-PSMA Combination Therapies
Joanna C Chan, Mitchell T Carroll, Nadia Hitchen, et al.
European Urology Oncology
|
December 10, 2023
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis
Francisco Gomez-Veiga, Russell Z Szmulewitz, Jeffrey Holzbeierlein, et al.
Cancer Immunology Research
|
October 21, 2018
Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs
Brian J Christmas, Christine I Rafie, Alexander C Hopkins, et al.
Future Oncology (London, England)
|
June 30, 2025
Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review
Paul E Dato, Jose De La Cerda, Andrew J Armstrong, et al.
Future Oncology (London, England)
|
May 11, 2026
Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols
Neal D Shore, Karim Fizazi, Michael Thomas Schweizer, et al.
Page
of 36